late-stage trial data are far more than a typical research peptide has, but the product is unapproved and cross-trial percentages are orientation, not a ranking
Trop Geogr Med
Storage Instructions Proper storage preserves peptide quality
Learn more about our DUTCH testing
Over 29 days in a phase 1 trial with healthy volunteers, those in the treatment group demonstrate a mean weight loss of 6.5%, which is statistically superior to placebo (not reported) ( 3.1.2.7 Semaglutide 50 mg Oral semaglutide is currently available up to a maximum dose of 14 mg for the treatment of T2D ( 2 , a 52-week phase 3 randomized trial shows a mean weight loss of 4.4%, 6.7%, and 8.0% at doses of 14 mg, 25 mg, and 50 mg, respectively ( 3.2 GLP1/GIP receptor agonists 3.2.1 Subcutaneous 3.2.1.1 CT-868 CT-868 is a signaling biased dual GLP-1/GIP receptor co-agonist administered daily as a subcutaneous injection ( 2 demonstrates a mean HbA1c reduction of 2.0% at the 4.0 mg dose compared to an increase of 0.3% for placebo ( 3.2.1.2 CT-388 CT-388 is another signaling biased dual GLP-1/GIP receptor co-agonist administered weekly by subcutaneous route ( 3.2.1.3 VK2735 subcutaneous VK2735 is a dual GLP-1/GIP receptor co-agonist that is administered weekly by subcutaneous injection ( 3.2.1.4 HRS-9531 HRS-9531 is a GLP-1 and GIP receptor co-agonist administered weekly by subcutaneous route
Telomere Biology This tetrapeptide has gained significant attention in longevity and anti-aging research based on findings suggesting it can influence telomere length, activate telomerase in somatic cells, normalize circadian rhythms, and potentially extend lifespan in animal models
